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Rapid Detection of Mycobacterium tuberculosis in Lung Tissue
Using a Fiber Optic Biosensor
Kimberly A. Denton
ABSTRACT
There is no rapid diagnostic technique at medical examiners’ offices to determine if a
decedent is infected with Mycobacterium tuberculosis. Present diagnostic testing
requires at least one month for results. A biosensor-based sandwich immunoassay for the
detection of M. tuberculosis was developed in this study. M. tuberculosis polyclonal
antibody was used for target antigen capture and detection in the immunoassay. Live
attenuated M. tuberculosis (ATCC 25177) suspended in phosphate-buffered saline with
0.1% Tween 20 was used as the antigen in the detection assay. The Analyte 2000 was
the initial biosensor platform. Initial testing was of Freund’s adjuvant complete. M.
tuberculosis was detected 50% of the time at 106 CFU/ml and 100% of the time at 107
CFU/ml and 108 CFU/ml. Live attenuated M. tuberculosis was also tested using the
Analyte 2000 biosensor. Detection was obtained 87.5% of the time at 106 CFU/ml and
100% of the time at 107 CFU/ml and 108 CFU/ml. The RAPTOR, an automated, portable
instrument, was then tested as the fiber optic biosensor platform. Positive biosensor
detection was obtained 75% of the time at cell concentrations of 106 CFU/ml, 95% of the
time at 107 CFU/ml, and 99% of the time at 108 CFU/ml. Live attenuated M. tuberculosis
suspended in PBST and seeded into decedent lung tissue was tested using the RAPTOR.
viii

Positive detection was obtained 21% of the time at cell concentrations of 106 CFU/ml,
86% of the time at 107 CFU/ml and 100% of the time at 108 CFU/ml. Antibody
specificity studies using ELISA were performed to determine the anti-M. tuberculosis
antibody’s cross reactivity with microorganisms other than M. tuberculosis. M.
tuberculosis actively growing in the lung of an individual is found at levels of 107 to 109
CFU in the lesions of the lung. This study determined that the RAPTOR biosensor assay
was capable of detecting the presence of M. tuberculosis in lung tissue homogenate
within three hours when the concentration of M. tuberculosis was 107 to 109 CFU/ml.
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Introduction
The etiological agent Mycobacterium tuberculosis is responsible for causing
tuberculosis (TB) in humans (43). Dated as far back as 2400 BCE, M. tuberculosis
pathological findings have been found in spinal column fragments of Egyptian mummies
(11). The first Mycobacterium tuberculosis staining technique was developed by Robert
Koch in 1882 (41, 42). M. tuberculosis, known in the 17th and 18th century in Europe as
the White Plague, causes more deaths in humans than any other bacterial pathogen (24).
In early times, doctors could only treat TB infections by improving patients’ health by
admitting them into sanatorias (TB hospitals), which forced patients to rest, have a proper
diet and be isolated from the general public (19). Streptomycin was the first antibiotic
prescribed for TB in 1944 (35). Worldwide, there are more than two million tuberculosis
deaths each year (15). Global TB cases continue to rise. Approximately one percent of
the world’s population is newly infected with M. tuberculosis each year, and every
second someone in the world is newly infected. Presently, one-third of the world’s total
population (2 billion) is infected with M. tuberculosis, and of those infected, five to ten
percent will become sick or infectious later in life. TB is a worldwide pandemic. Africa
accounts for 29% of all TB cases, and Asian countries Bangladesh, China, India,
Indonesia, Pakistan and Philippines account for 50% of all new TB cases. Each year, ten
to fifteen newly infected people result from one person with active TB not being treated
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(83). Adult mortality resulting from tuberculosis is the second most common cause of
infectious death (25).
TB cases in the United States have been on the decline since 1993. There were
16,309 TB cases per 100,000 population in 2000 and 14,097 per 100,000 population in
2005. By the year 2010, the Centers for Disease Control and Prevention (CDC) hope to
have eliminated tuberculosis from the United States (15).
M. tuberculosis grows as serpentine cords and is neither gram-negative nor grampositive; it is a non-motile bacillus (rod-shaped) and is characterized as an acid-fast
bacterium (57). The bacteria have peptidoglycan in the cell wall, but over 60% of the cell
wall is lipid and composed of mycolic acids (16). M. tuberculosis requires oxygen, and
its growth rate is proportional to the concentration of oxygen. Therefore, the bacillus
grows well in the oxygen rich cavities of the lungs (44). These bacilli are also called
tubercle bacilli as a result of forming the characteristic lesions of M. tuberculosis
infection. In an actively proliferating infection, there are populations of tubercle bacilli
varying from 107 to 109 CFU (31, 44).
Lowenstein-Jensen (LJ) medium and Middlebrook medium are the media used to
grow M. tuberculosis (36, 55), resulting in generation times of 15-20 hours. Colonies
appear buff colored (78) and small after four to six weeks of growth. M. tuberculosis can
survive for long periods of time outside of its host. On carpet, the bacteria can survive
for 70 days. On clothing, M. tuberculosis can survive for 45 days and on a paper book
105 days. Sputum that is stored in a cool dark area can support survival for six to eight
months. M. tuberculosis can survive on dust for 90 to 120 days. It can survive on
manure for up to 45 days and on cockroaches for 40 days (57). The high lipid content of
2

M. tuberculosis influences permeability of the cell wall to stains and makes the bacterium
resistant to some antibiotics and capable of survival inside macrophages (16).
The complete genome of M. tuberculosis H37Rv was established in 1998. The
genome consists of 4,411,532 base pairs with a 65% G + C content, which is associated
with its highly aerobic environment requirement, a characteristic of aerobic microbes. Of
the 4,043 genes, 26% are conserved hypothetical proteins; 5% are regulatory proteins;
7% are proteins of unknown function; 4% are insertion sequences; 17% are involved in
cell wall and cell processes; 4% are PE proteins (a protein family in M. tuberculosis with
unknown function, named P for conserved proline and E for glutamate residues); 1% are
involved in stable RNAs; 6% are involved in information pathways; 6% are involved in
lipid metabolism; 22% are involved in intermediary metabolism and respiration, and 2%
are involved in virulence, detoxification and adaptation (16, 73).
Some individuals are more at risk for developing TB infection than others. Those
individuals with poor nutrition, drug abuse, alcohol abuse, young children, those in close
contact with large groups of people, those living in dormitories, those attending schools,
hospice and hospice employees, nursing home residents and workers, those in long term
psychiatric facilities and workers, patients and staff of chronic care units of hospitals for
veterans, health care workers, pathologists, autopsy technicians, forensic clerical staff,
family members and friends of those infected, funeral home workers, those who ride in
airplanes (2, 38), the homeless, those presently or previously imprisoned and those
diagnosed as HIV positive are at the greater risk (5, 16, 27, 78). People with chronic
renal failure, diabetes mellitus and neoplastic diseases are at increased risk of developing
tuberculosis (16). Host factors that are critical in influencing whether or not M.
3

tuberculosis develops into symptomatic tuberculosis are genetic factors, coexisting
diseases, immune status, age, specific immunodeficiency states, and immunization with
Bacille of Calmette and Guérin (BCG) vaccine, a live vaccine made from an attenuated
strain of M. bovis (10, 16). Also critical are the microbial factors of virulence of the
organism and the specific tissue it infects. Of the individuals infected with M.
tuberculosis, only three to four percent will develop active disease. In healthy people,
infection with M. tuberculosis is usually asymptomatic. There is a ten percent likely risk
of developing clinical manifestations of M. tuberculosis with a ninety percent probability
of the infection remaining latent (16, 18).
Prior to the discovery of HIV, eighty-five percent of cases reported involved
pulmonary tuberculosis and fifteen percent either involved nonpulmonary areas or a
combination of pulmonary or nonpulmonary sites. After HIV discovery, there was thirtyeight percent pulmonary involvement, thirty percent extrapulmonary site involvement
and thirty-two percent likelihood of both nonpulmonary and pulmonary involvement (16,
26, 33, 70).
The bacterium is characterized as a facultative intracellular parasite taken up by
phagocytosis and is not able to actively invade host cells (47). Portal entry is the lung.
Four to twelve weeks are the incubation period from infection to primary lesion or
tuberculin reaction. Infections may persist for a lifetime as latent infections.
Extrapulmonary infections from M. tuberculosis usually occur one or two years after
exposure (57).
There are five stages of disease caused by M. tuberculosis. Stage one is
characterized by inhalation of droplet nuclei. Droplet nuclei are generated by talking,
4

coughing, sneezing, singing and other forms, which make airborne particles of droplet
nuclei. Macrophages uptake these bacteria, but are unable to destroy them (78).
Macrophage entry by M. tuberculosis occurs by ligation with receptors enabling
phagocytosis (16). Stage two is characterized at seven to twenty-one days. Macrophages
burst as M. tuberculosis multiplies. Stage three is characterized by T-cell and
macrophage activation. Individuals become tuberculin-positive. Tubercle formation
begins with caseation necrosis. Stage four is characterized by tubercles being surrounded
by macrophages. Tubercle growth continues, possibly invading other areas of the lung
and/or arteries. Stage five is characterized by liquefaction of tubercles. Bronchi rupture
and become necrotic, leaving cavities that allow bacteria to invade other parts of the lung.
The Ghon complex is characterized by lesions in the lungs becoming fibrous, calcifying
and healing, and can be observed upon chest x-ray. Depending upon the host strength,
the infection may be controlled (78).
M. tuberculosis affects all parts of the world, leading to disability and death. The
infectious dose is 10 bacilli by inhalation. The mode of transmission is airborne bacilli
from an infected person’s sputum, breaks in the skin and mucous membrane invasion.
Those who perform or assist at autopsies, intubations and bronchoscopies are at extreme
risk of exposure. Humans serve as reservoirs for M. tuberculosis (57). Both sexes are
infected equally with M. tuberculosis, except for those HIV positive, in which males
predominate. The number of those with HIV associated TB continues to rise and cause
incidence rates to go upward globally (16).
Symptoms of TB include: fever, fatigue, cough, chest pain, extrapulmonary
involvement, weight loss, and night sweats, which can lead to disability and death (57).
5

Depression has also been associated with infection (16). The lungs are the main site of
damage caused by M. tuberculosis. However, other areas of the body may be infected:
bones, which may lead to paralysis; kidneys, destroying tissue, which then may spread to
the bladder; female reproductive organs, which can then spread to the abdominal cavity,
causing symptoms of appendicitis; and joints, causing a form of arthritis affecting hips,
knees, elbows, hands and wrists. The skin, vessels, adrenal glands, and intestines can be
infected by M. tuberculosis (6).
Treatment involves single or combination of antibiotic therapy involving
isoniazid, rifampin, pyrazinamide, ethambutol and streptomycin. The length of treatment
can vary from six months and in some cases up to twelve months (5).
Exposure to M. tuberculosis is determined by a skin test with purified protein
derivative (PPD), followed by a chest x-ray (47). Skin testing involves a test called the
tuberculin or Mantoux test (56). M. tuberculosis is boiled to generate PPD. Injection of
five tuberculin units (0.00001 mg) PPD in a 0.1 ml volume into the forearm is done in the
Mantoux test. Within 48-72 hrs the forearm area is positive if the injection site has an
observed lesion, 10 mm or larger, redness called erythema, swelling and induration
(raised and hard) (51). A disadvantage of the Mantoux test is the possibility of false
positives. False positives are usually less intense reactions and may be the result of
vaccination with BCG, infection with other mycobacteria or prior exposure to M.
tuberculosis. False negatives sometimes result in AIDS patients with impaired cell
mediated immune (CMI) response, individuals with malnutrition and those taking
steroids (78). A positive PPD test does not confirm infection with M. tuberculosis. Nor
does a negative test confirm the absence of infection. The purified protein derivative
6

contains greater than two hundred types of mycobacterial antigens, which causes poor
specificity and the ability to differentiate from vaccination, prior M. tuberculosis
infection and infection with nonpathogenic environmental mycobacteria causing crosssensitization. If a positive PPD test is acquired, a chest x-ray is performed (16). Chest xrays (Abreugraphy), named after pulmonologist Manoel Dias de Abreu, were developed
in 1921 to screen for tuberculosis (1). When an abnormal chest x-ray is obtained, sputum
and bronchoscopy examinations are investigated. Those individuals that are tuberculin
positive should be informed and advised of the disease symptoms and seek treatment
(16).
The live vaccine, Bacille of Calmette and Guérin (BCG), is attenuated M. bovis
(57). A disadvantage of using BCG vaccine is that disease is prevented, but infection is
not. Consequently, all individuals worldwide would need to be vaccinated. The vaccine
is also not 100% effective. If vaccination were performed in the U.S., tuberculin skin test
results would be useless. An effective antibody detection based test that is sensitive and
specific for M. tuberculosis is not available, although development of serodiagnostic tests
have been studied for decades. Some of the antigens used to develop serodiagnostic tests
are the 14/16-kDa alpha-crystalline homologue protein, 10-kDa heat shock protein, 19kDa lipoprotein, 38-kDa protein and antigens 85 A and B (16).
Clinical specimens tested for presence of M. tuberculosis include cerebrospinal
fluid (CSF), blood, urine, lesions from tissues, sputum, bone marrow and gastric lavage
fluids, and biopsy specimens of lymph nodes, lungs, liver, kidneys, adrenals and spleen
(5, 9, 16, 17). Various nonselective media are used to recover mycobacteria from clinical
specimens, including Lowenstein-Jensen, Petragnani, American Thoracic Society (ATS)
7

medium, Middlebrook 7H10 and Middlebrook 7H11. Lowenstein-Jensen media is the
most common media used for recovery of mycobacteria. The medium is composed of
defined salts, glycerol, potato flour, coagulated whole eggs and malachite green as an
inhibitory agent. Petragnani medium is used to recover Mycobacteria from samples
heavily contaminated with bacteria. ATS medium has lower levels of malachite green,
making it less inhibitory of mycobacteria. ATS medium is often used to recover
Mycobacteria from sterile specimens of CSF, tissue and pleural fluid. Middlebrook 7H10
and Middlebrook 7H11 agar media are used for susceptibility and isolation testing.
Middlebrook 7H11 varies only from Middlebrook 7H10 by containing casein
hydrolysate, which improves growing rate of Mycobacteria resistant to isoniazid.
Examples of selective Mycobacterial isolation media (media containing antimicrobial
agents used to suppress fungal and bacterial contamination) are Gruft modification of
Lowenstein-Jensen, Lowenstein-Jensen, Middlebrook 7H10, and selective 7H11. The
Gruft modification of Lowenstein-Jensen medium contains the inhibitory agents of
malachite green, nalidixic acid, penicillin and the components of potato flour, RNA,
coagulated whole eggs and defined salts. Lowenstein-Jensen selective isolation medium
has the same components as the nonselective media. Both media contain the inhibitory
agent malachite green. However, the selective Lowenstein-Jensen medium also contains
the inhibitory agents cycloheximide, lincomycin and nalidixic acid. Middlebrook 7H10
as a selective medium contains all the nonselective components of Middlebrook 7H10
medium with the addition of glucose, instead of dextrose, and the addition of the
inhibitory agents of cycloheximide, lincomycin and nalidixic acid. Selective
Middlebrook 7H10 contains the same components as the nonselective media
8

Middlebrook 7H11 with the addition of glucose and the inhibitory agents of carbenicillin,
amphotericin, polymyxin B and trimethoprim lactate. Middlebrook 7H11 as a selective
medium, however, lacks the inhibitory agent malachite green, which is present in the
nonselective medium. Middlebrook 7H10 or 7H11 clear agar culture medium allows
growth of microcolonies (microscopic observation) that can be observed in five to seven
days. Presumptive identification is possible based on morphological microscopic
examination of microcolonies, aiding in diagnosis. The Septi-Chek AFB System (BBL)
and the Mycobacteria Growth Indicator Tube (MGIT) system have also been utilized to
recover mycobacteria from clinical specimens. The BBL system utilizes a modified
Middlebrook 7H9 broth in 20% CO2, nonselective Middlebrook 7H11 agar, modified LJ
medium and chocolate agar. Acid fast staining and DNA probe analysis can be
performed if growth is observed. The MGIT system incorporates an oxygen sensitive
fluorescent sensor indicating microbe growth in Middlebrook 7H9 broth. Middlebrook
7H9 broth is a medium used for cultivation and isolation of Mycobacterium. Turbidity or
detection of colonies can be visualized earlier, but growth of bacteria must still occur
(44).
Laboratory tests to detect M. tuberculosis include staining, conventional
biochemical tests, inoculation of clinical specimens into agar-based culture media, use of
broth culture media, application of polymerase chain reaction (PCR) technology, non
isotopic nucleic acid probes, use of automated and semi-automated instruments,
restriction endonuclease assays and use of lysis-centrifugation system blood culture tube.
Laboratory testing also includes gas-liquid chromatography, high performance liquid
chromatography and mass spectrometry (44).
9

Four to eight weeks are required for traditional culturing techniques, which must
then be followed by biochemical tests, in order to identify M. tuberculosis (5). Acid-fast
staining is the only rapid, widely available laboratory test that can be performed to
presumptively diagnosis a sample as Mycobacterium positive. However, false positive
results can be obtained from acid-fast stains of Bacillus and Clostridium endospores,
Nocardia, some ascospores of yeasts, and other Mycobacterium species, which also are
acid-fast. In the acid-fast stain, the specimen is heat fixed to a slide and steamed with
carbolfuchsin, a primary stain. The specimen prepared slide is then rinsed, decolorized
with acid-alcohol, rinsed and counterstained with methylene blue. Acid-fast positive
microorganisms are pink and nonacid-fast microorganisms are blue. The cell envelope
contains high lipid content, preventing decolorization from acid-alcohol (53). Acid-fast
staining is used only as a presumptive test for M. tuberculosis, which can be performed in
a matter of minutes, but must be followed with a series of biochemical tests, which can
take one to two months, because of the slow growth of this microorganism (5).
Conventional identification tests that help distinguish mycobacteria species are
pigment production test in the presence (photochromogen) or absence (scotochromogen)
of light (44). Additional conventional identification tests are Tween 80 hydrolysis,
arylsulfatase activity, urease activity, iron uptake, growth in 5% sodium chloride, growth
on MacConkey agar, niacin accumulation, nitrate reduction, pyrazinamidase production,
thiophene-2-carboxylic acid hydrazide (TCH) susceptibility, production of heat-stable
catalase and drug susceptibilities (16, 44).
Automated and semi-automated instruments are also used to identify
Mycobacterium. With these instruments, drug resistance can be determined in three to
10

five days, after inoculation with the Mycobacterium strain of interest (44). The BACTEC
AFB System detects growth using an automated BACTEC 460 instrument. The
BACTEC AFB System involves passing culture bottles through the machine. Aspiration
of the bottles occurs, and the aspirated gas is delivered to a counting chamber. Fresh
10% CO2 is added to replace the aspirated gas. The samples are incubated, and if
Mycobacteria are present in the sample, CO2 is released in proportion to the amount of
growth. Carbon 14 labeled palmitic acid is used as the growth detector. The system
detects the radioactive CO2, and a growth index (GI) is calculated. A ten or higher GI is
positive for the detection of Mycobacterium. The machine does not identify the
Mycobacterium species. Disadvantages of this system are its high cost, overgrowth by
contaminants and the need to dispose of radioactive materials (66). Growth of
mycobacteria is detected in 14 days, instead of the 21 days by standard culture method
(66). The ESP Myco System monitors an increase in gas pressure, resulting from gases
produced by metabolizing mycobacteria. Gas pressure increase takes at least seven days
for detection. Modified Middlebrook 7H9 medium, casitone glycerol and cellulose
sponges are placed within each culture bottle. The cellulose sponges provide an
environment simulating the alveoli of the lungs. Each bottle contains a sensor and
continuously monitors any changes in pressure. This system detects the presence of
mycobacteria. It does not identify the mycobacteria species. However, this system is
being tested and is not clinical setting ready (82).
Another automated instrument is the MB/Bac T, used in clinical specimen
detection, but not in blood, with a gas permeable CO2 sensor that changes color from
green to yellow when CO2 is produced from metabolizing mycobacteria. The bacteria
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must grow to be detected by this instrument. The MB/Bac T Mycobacteria detection
system is used to detect mycobacteria, but not to identify the species (64).
Polymerase chain reaction (PCR) technology is used to detect M. tuberculosis and
currently has the most potential for rapid detection. Detection by PCR requires
amplification of target M. tuberculosis DNA sequences extracted from clinical specimens
and subjected to gel electrophoresis (60). The products of PCR are transferred to
membranes, and probes are used that bind specific DNA of M. tuberculosis (5). Strain
identification by PCR is based on primers that amplify IS6110, an insertion sequence (IS)
of 1,365 base pairs (75). IS6110 is found only in the M. tuberculosis complex of
mycobacteria, consisting of M. tuberculosis, M. bovis, M. africanum, M. canetti and M.
microtii (12). The IS copies vary from twenty to one per genome (5, 16, 54).
DNA fingerprinting identifies M. tuberculosis, based on the distribution of the
IS6110 insertion sequence within the genome. These insertion sequences vary in location
and in number within chromosomes. IS6110 is conserved. Digestion of M. tuberculosis
occurs with enzymes yielding fragments of varying sizes and numbers that become
evident using gel electrophoresis. Fragments are transferred to a membrane, and a
radiolabeled DNA probe is used to hybridize. The pattern and number of fragments
make up the fingerprint characteristic of M. tuberculosis (5).
M. tuberculosis also can be identified by nucleic acid hybridization. Single
stranded 125I-labeled DNA probes - complementary to rRNA of M. tuberculosis complex
(M. tuberculosis, M. bovis, M. africanum, and M. ulcerans), M. avium, M. intracellulare,
M. gordonae and M. kansasii - are used in identification of Mycobacteria species. A
lysing of the bacterium sample occurs through the use of lysing agent, heat and
12

sonification. The DNA probe forms a complex with RNA and the radioactive hybrids are
quantified. A luminometer measures the visible light to determine a positive.
Confirmation of M. tuberculosis requires colony growth on Lowenstein-Jensen slants.
Four to six weeks are required for final identification (23, 39, 59, 67).
Non-isotopic acridinium-esther labeled nucleic acid probes can also be used to
confirm identification of M. tuberculosis complex, M. avium, M. intracellulare and M.
gordonae, with similar testing as to the isotopic labeled DNA probe. Ester-labeled singestranded complementary DNA probe binds to rRNA of bacteria. These tests take five
hours to perform (30, 49). Viability confirmation is still necessary, requiring four to six
weeks (44, 71, 79). Implementation of restriction endonuclease analysis of PCR
amplified products form target rRNA or DNA conserved sequences is also used to
identify M. tuberculosis species and to determine strain variance (13, 34, 84). Combining
a DNA probe specific for RNA sequences of M. tuberculosis with radiometric culture
procedures will produce results in seven to twenty-one days (5).
Gas-liquid chromatography and high-performance liquid chromatography have
been used to identify M. tuberculosis. These tests analyze mycolic acids and fatty acids
of the cell wall of M. tuberculosis using high performance liquid chromatography
(HPLC) and gas-liquid chromatography (GLC) to rapidly identify species of M.
tuberculosis. The process takes less than two hours (32, 65, 67, 77). Unfortunately,
tuberculostearic acid is also present in Actinomycetales and nontuberculous bacteria, so
test specificity can be a problem. HPLC and GLC have not yet been tested using clinical
specimens. These biochemical techniques, which use expensive equipment, are limited
to reference laboratories (5).
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Enzyme-linked immunosorbent assay (ELISA) can be used to detect M.
tuberculosis in body fluids. Samples require overnight incubation and equipment, such
as a plate reader. When detecting M. tuberculosis in sputum, if not processed correctly,
antigen may be subject to being denatured in the decontamination processing, which may
lead to specificity problems (5, 8). Immunoassays for anti-mycobacterial antibodies
using ELISA have also been performed. Patient samples are mixed with mycobacterial
antigens. Antibodies are detected by adding antibodies to human immunoglobulin for a
colorimetric assay. Combining radiometric culture methods and DNA probing, M.
tuberculosis could be identified in three weeks (5). Two types of mycobacteriophagebased tests have also been used to detect M. tuberculosis: the luciferase reporter phage
(LRP) assay and the FASTPlaque assay. LRP assay uses phages that harbor the fflux
reporter gene coding for luciferase. In the presence of the substrate luciferin, light
emission is measured using a luminometer or photographic film. Luciferase activity is
detected in clinical specimens only if cellular ATP is present. The emission of light is
proportional to the viability of mycobacteria. Amplification of Mycobacteria is required
over approximately twelve days. The FASTPlaque assay uses wild-type
mycobacteriophages that are mixed with M. smegmatis. Phages are released from M.
tuberculosis and infect M. smegmatis. Plaques are detectable one day later on plates of
M. smegmatis. This is a phase-susceptibility test and does not positively confirm
infection with M. tuberculosis (3, 4, 7, 40, 81).
Microplate colorimetric assays are used to detect drug-resistant M. tuberculosis.
These tests utilize indicators of oxidation-reduction reactions that occur during
mycobacteria growth in the presence of antituberculosis drugs. The test is incubated for
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five to seven days. A color change due to a reduction reaction demonstrates the presence
or absence of drug resistant M. tuberculosis (14, 63).
At autopsy there is the risk of exposure to a great many infectious agents that can
be aerosolized and bloodborne, including human immunodeficiency virus, M.
tuberculosis and hepatitis C and B. Even with proper facility design, appropriate autopsy
procedure protocols and the use of personal protective equipment, transmission does
occur from decedents to autopsy personnel. The high rate of exposure of medical
laboratory workers, pathologists and autopsy technicians often leads to the development
of M. tuberculosis infection (29, 61). There are numerous reports of pulmonary
tuberculosis acquisition by laboratory and autopsy room staff, in which there is a one
hundred to two hundred times rate of acquisition than the general public. During their
professional careers, both pathologists and pathology assistants will be exposed to M.
tuberculosis with high probability of infection (28). There are several studies
demonstrating M. tuberculosis transmission through routine embalming from cadavers to
funeral directors and mortuary workers (48). Formalin fixed tissue containing M.
tuberculosis poses a risk of being infective by aerosolization and inoculation (29). The
assays described above have many limitations. Most assays require expensive
equipment, technical expertise, and require days to weeks for results. There is a
significant need for improved and rapid diagnostic testing for tuberculosis infections.
The Medical Examiner’s mission is to investigate and try to explain the cause of
death of decedents when death is unattended, unexpected or violent, as well as give
approval for cremation, removal of a body from the state, burial at sea, or anatomical
dissection (58). Lung tissue samples suspected of M. tuberculosis infection are sent to
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the State of Florida, Department of Health, Bureau of Laboratories, Mycobacteriology
Laboratories in Jacksonville, Florida. Special instructions are to collect the specimen
aseptically and avoid indigenous microbiota. A caseous portion is to be selected, if
available. The specimen is not to be immersed in saline (or other fluid) or wrapped in
gauze. The specimen is not to be frozen, as freezing decreases yield. Specimens cannot
be submitted in formalin. Specimen requirements are one gram of tissue without fixative
or preservative. The specimen may be shipped in a sterile container with a small amount
of sterile water or sterile saline (to keep the specimen moist). The state laboratory
processes body fluids, swab specimens, tissue and bone. At the state laboratory, tissue
samples are processed by cutting the tissue into several small pieces with sterile scissors
and placing the pieces into a sterile grinder. Saline solution is placed into the grinder.
The tissue is grinded well using a back and forth motion, while applying pressure, until
only the fibrous portion of the tissue remains. The fluid is then removed from the tissue
grinder. Digestion and decontamination of specimens must then occur. N-acetyl-Lcysteine/sodium hydroxide method (NALC-NaOH) is used to decontaminate specimens.
A volume of NALC-NaOH solution equal to the volume of the specimen is added. Each
specimen is mixed with a vortexed action until liquefied. The specimens are not to be
over mixed, because aeration of the specimen may inactivate the NALC and cause the
specimen to gel. The specimen is let to stand at room temperature. A 6.8 pH phosphate
buffer is added, after decontamination. The tube is recapped and inverted to mix. Each
sample is centrifuged, and the supernatant is decanted without disturbing the sediment.
The sediment is resuspended with phosphate buffer and used to inoculate media and
prepare smears. If specimens are contaminated with Pseudomonas species or from
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patients with cystic fibrosis, the Oxalic acid method of decontamination is performed.
The inoculation of media and smear preparation is performed with a sterile cotton tip
swab and a generous amount of sediment is inoculated into Lowenstein-Jensen (LJ)
slants. The incubation of LJ slants with caps loose occurs at 35º C in the presence of five
to ten percent CO2. Slants are examined twice a week for two weeks and then once a
week for up to eight weeks for growth. The Lowenstein-Jensen slants are examined for
growth by using a light with a magnifying lens. If growth is observed, the Ziehl-Neelsen
acid-fast stain is performed and examined with a microscope. If the growth is not acidfast, the slant is reincubated and reexamined. If the slant becomes overgrown with nonacid-fast organisms, the slant is discarded. The smear is examined by making a series of
nine vertical parallel or three horizontal sweeps of the slide, viewing at least 300 fields.
Quantification of smear results is noted. DNA probe identification is then performed.
DNA probes of M. tuberculosis complex, M. avium, M. intracellulare and M. gordonae
are used to identify the mycobacteria. DNA fingerprinting and strain typing using RFLPrestriction fragment length polymorphism can be used to further identify mycobacteria.
Nucleic acid amplification (PCR) and hybridization assays can also be performed to
identify the mycobacteria. Results are then issued to the Medical Examiner’s Office,
where the autopsy report can then be finalized and those at risk of exposure notified.
These are all time consuming procedures (20, 44, 46, 50, 71, 79).
At the Hillsborough County Medical Examiner’s Office, as well as other medical
examiners’ offices, there is no rapid diagnostic technique to determine if a decedent is
infected with M. tuberculosis (20, 50). Bodies are received from hospitals, residences,
accidents, jails, and funeral homes. The states of decomposition of the bodies vary
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greatly. All those present during an autopsy - doctors, autopsy technicians, medical
students and detectives - are at possible risk of exposure to M. tuberculosis (44, 47).
There is evidence of tuberculin skin test conversions occurring in autopsy personnel, as a
result of exposure to decedents infected with M. tuberculosis (80). Through
investigation, it has been demonstrated that postmortem examination of decedent lung
tissue and autopsy staff sputum, both infected with M. tuberculosis, can have identical M.
tuberculosis DNA fingerprints, as a result of staff being exposed at autopsy (74). At the
University of New Mexico, School of Medicine, a study was performed that investigated
the postmortem survival ability of M. tuberculosis in lung tissue from an unembalmed
exhumed body. Eight days after death, there was viability of M tuberculosis in the lung
tissue, demonstrating that bodies with postmortem intervals with extended time between
death and autopsy can potentially be infectious with M. tuberculosis. The actual cause of
death of this decedent was pulmonary tuberculosis (62). Pulmonary tuberculosis cannot
be diagnosed by physical findings (16).
If a decedent is suspected to have had tuberculosis at time of death, at autopsy,
after the chest cavity is opened and lungs removed, the lungs are sliced on a cutting board
and samples are taken of caseous or lesion areas. Testing of the samples takes a
minimum of one month (20, 31, 47, 50). During this time, those who may have been
exposed are postponing treatment, at the minimum, for one month. In addition, autopsy
results are incomplete (50).
Development of a rapid method to detect M. tuberculosis from lung tissue at
autopsy would be a significant benefit to medical examiners’ offices and pathologists
worldwide. Rapid diagnosis would allow autopsy personnel, who had been exposed to an
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infected decedent, to be tested earlier for possible contraction of M. tuberculosis and
begin immediate treatment, if needed.
The Analyte 2000 and the RAPTOR (Research International, Monroe, WA) are
the two biosensors used for this study. The Analyte 2000 must be operated in a manual
mode, whereas the RAPTOR is portable and automated with a footprint the size of a car
battery. These evanescent wave fiber optic biosensors have a laser that emits a 635 nm
beam of light. The laser excites the fluorescent molecule cyanine 5 (Cy5), causing the
Cy5 to emit light at wave lengths above 670 nm. The emitted light is recorded in
picoAmps by the biosensor. The signal increases in proportion to the amount of target
bacteria present on a waveguide. These biosensors have been used to detect
Staphylococcal enterotoxin B, ricin, Clostridium botulinum toxin A, E. coli
lipopolysaccharide endotoxin, Bacillus anthracis, Escherichia coli O157:H7, Salmonella
typhimurium, Vaccinia virus, Francisella tularensis, Cryptosporidium parvum, in
matrices of apple juice, ground beef, other foods, drinking water, seawater and human
clinical specimens (21, 22, 52).
A sandwich immunoassay is the basis for the biosensors’ detection platforms.
These biosensors use polystyrene waveguides coated with streptavidin (a protein
produced by Streptomyces avidinii which has four binding sites for biotin). A biotin
labeled polyclonal capture is then incubated on the waveguides. The sample of interest is
applied to the waveguides and allowed to incubate. A Cyanine-5 (Cy-5) labeled
detection polyclonal antibody is then incubated on the waveguide.
Therefore, rapid detection of M. tuberculosis at autopsy using lung tissue from
decedents would be a helpful diagnostic tool. There are currently no rapid procedures to
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detect M. tuberculosis. The objective of this study was to develop a rapid biosensor
assay that will detect M. tuberculosis in lung tissue.
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Materials and Methods
Chemicals and Buffers
All reagents were from Sigma Chemical Company (St. Louis, MO) unless
otherwise noted. The following solutions were used for all experiments unless otherwise
noted. Phosphate-buffered saline, pH 7.4, (PBS) consisted of 0.1 M sodium phosphate,
pH 7.4 and 0.85% (wt/vol) sodium chloride. PBS containing Tween 20 (PBST) consisted
of PBS, with 0.1% Tween 20. Blocking buffer was made with PBST, 2 mg/ml casein,
and 2 mg/ml BSA. NuPAGE sample transfer buffer was used in performing Western
blotting from Invitrogen (Carlsbad, CA). Fixing solution for fixing proteins to gels
consisted of 7.5 % methanol (vol/vol), 10% acetic acid (vol/vol), and 82.5% water.
Borate buffer consisted of, pH 9.7, Borax, and MgSO4·7H2O. Column buffer was made
with PBS and 0.02% (wt/vol) sodium azide. Sodium carbonate solutions consisted of 0.1
M sodium carbonate at pH 8.5 or at pH 9.3.
Bacterial Strains
Freund’s adjuvant complete Lot 51H8925 was obtained from Sigma Chemical
Company. The following bacteria were obtained from The American Type Culture
Collection (ATCC): attenuated Mycobacterium tuberculosis ATTC 25177, E. coli K-12
ATCC 23724, Klebsiella pneumoniae ATCC 13883, Mycobacterium gordonae ATCC
14470, Mycobacterium intracellulare ATCC 13950 and Staphylococcus aureus ATCC
6538. Candida albicans, Haemophilus influenzae, Mycobacterium rhodochrous,
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Mycobacterium smegmatis, Proteus mirabilis, Pseudomonas aeruginosa, Streptococcus
agalactiae and Streptococcus pneumoniae were obtained from the University of South
Florida Advanced Biosensors Laboratory culture collection. Attenuated M. tuberculosis
was cultured on BBL Lowenstein-Jensen medium slants (BD, Sparks, MD).
Haemophilus influenzae was grown on Haemophilus isolation agar plates (Remel,
Lenexa, KS). All other bacteria were cultured on sheep blood agar plates (Remel,
Lenexa, KS). All bacteria were incubated in 5% CO2 at 37º C.
Antibodies
Rabbit anti-M. tuberculosis antibody (against all antigens) and biotin conjugated
rabbit anti-M. tuberculosis antibody (against all antigens) were obtained from Biodesign
International (Saco, ME). The immunogen was purified protein derivative of M.
tuberculosis. When these antibodies were tested, the major reactivity was to two proteins
at the gamma and beta positions. The identity of these proteins has not been determined.
These antibodies have not been absorbed and may be reactive with related organisms.
The affinity purified anti-rabbit IgG conjugated to horse radish peroxidase (HRP) was
obtained from Kirkegaard and Perry Laboratories (Gaithersburg, MD).
Antibody Labeling
Rabbit antibody to M. tuberculosis catalog # B65601R (Biodesign International)
with a concentration of 2 mg/ml was added to 277 µl of 0.1 M carbonate buffer, pH 9.3,
in a Cy5 dye vial (FluoroLink Cy5 reactive dye pack; Amersham Biosciences,
Piscataway, NJ) and incubated for 1 hr at 24º C on a rocker. A P-10 column (Bio-Gel P10 gel, Bio-Rad, Hercules, CA) was prepared and used to separate labeled antibody from
non-conjugated dye. The column has an exclusion limit of 20,000 Daltons and a bed
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volume of 10 ml. The labeled antibody was collected and the absorbance at 280 nm and
650 nm was recorded using a DU-64 Spectrophotometer (Beckman, Fullerton, CA). The
absorbance values were then used to calculate the protein concentration and the dye to
protein ratio.
Preparation of Freund’s Adjuvant Complete
Each ml of Freund’s adjuvant complete (Sigma) contained 1 mg M. tuberculosis
(H37Ra, ATCC 25177), heat killed and dried, 0.85 ml mineral oil and 0.15 ml mannide
monooleate. Freund’s adjuvant complete was first separated into an oil layer and a cell
layer. Using a 15 ml conical tube, a 10 ml sample of Freund’s adjuvant complete was
centrifuged for 20 min at 1430 x g at 4º C. The oil layer was serial diluted using PBS.
The yellow-white pellet was washed twice with PBST and resuspended in 1 ml of PBST.
The resuspended pellet was serial diluted in PBS. Freund’s adjuvant complete was also
serial diluted in PBS. A direct count of resuspended pellet could not be performed due to
interference from oil droplets.
ELISA
Direct enzyme-linked immunosorbent assays (ELISAs) were used as an initial
screening method to test the reactivity of anti-M. tuberculosis antibody to in-house
treated Freund’s adjuvant complete, live attenuated M. tuberculosis and other types of
bacteria. Bacteria to be tested were serial diluted in PBS. A volume of 100 µl was added
to the appropriate wells of a 96 well microwell plate (Nunc Maxi-Sorp, Roskilde, OK)
and incubated for 18 hours at 4º C. The wells were washed with PBST using a plate
washer (ELX50, Bio-Tek Instruments, Inc., Winooski, VT). A volume of 100 µl of
blocking buffer was added to each well and allowed to incubate at 24º C for 30 min. The
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wells were washed three times with PBST. Rabbit antibody anti-M. tuberculosis, 100 µl
at 10 µg/ml in PBS or blocking buffer, was added to each well and incubated for 30 min
at 24º C. Wells were then washed three times with PBST. One hundred µl of anti-rabbit
IgG conjugated to HRP, 2 µg/ml in PBS, was added to each well and incubated at 24º C
for 30 min. Wells were then washed three times with PBST. A volume of 100 µl of
QuantaBlu Fluorogenic Peroxidase Substrate (Pierce, Rockford, IL), prepared according
to manufacturer’s instruction, was added to each well and incubated for 15 min at 24º C.
QuantaBlu stop solution, 100 µl, was then added to each well. The plate was read on the
fluorometer (Spectra Max Gemini XS, Molecular Devices, Sunnyvale, CA) at 340 nm
excitation and 420 nm emission.
M. tuberculosis (ATCC 25177) was grown on BBL Lowenstein-Jensen medium
slants with an incubation time of approximately three weeks at 37º C in 5% CO2 (BD,
Sparks, MD). M. tuberculosis was removed using a sterile loop and placed in a sterile 50
ml conical tube containing PBST. The tube was sonicated for five minutes in a Branson
1510 Sonicator from Branson Ultrasonic Corporation (Danbury, CT) and counted directly
using a disposable counting chamber cellometer (Nexcelom, Lawrence, MA).
Western Blots
Attenuated M. tuberculosis, E. coli K-12, Haemophilus influenzae, Streptococcus
agalactiae, Klebsiella pneumoniae, Streptococcus pneumoniae, Staphylococcus aureus,
Mycobacterium rhodochrous, Proteus mirabilis, Pseudomonas aeruginosa,
Mycobacterium smegmatis, Candida albicans, Mycobacterium gordonae and
Mycobacterium intracellulare were prepared so that each stock concentration was 1.2 x
108 CFU/ml. All Mycobacterium concentrations were adjusted by diluting in PBST.
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Other bacteria were diluted in PBS. Bacterial suspensions were mixed with equal
volumes of sample buffer and electrophoresed at 200 volts for 30 min using NuPAGE
SDS running buffer (NuPAGE) on 10% NuPAGE SDS gels (NuPAGE, Invitrogen Life
Technologies, Carlsbad, CA). The gels were then electrophoretically transferred to 0.45
µm pore sized nitrocellulose membranes (Sigma). The membrane was blocked for 30
min at 24º C using 5% skim milk in PBS. The membrane was then incubated for 30 min
at 24º C with anti-M. tuberculosis antibody at a concentration of 2.5 µg/ml. After
washing the membrane with PBST, bound antibodies were detected using an alkaline
phosphatase conjugated goat anti-rabbit IgG in 5% skim milk, at concentration 0.35
µg/ml. The antibody was incubated with the membrane for 30 min at 24º C. After
washing with PBST, the membrane was developed for 30 minutes using ortho-dianisidine
and B-napthyl acid phosphate in Borate buffer (11.44 g Borax, pH 9.7, 0.6 g
MgSO4·7H2O, 500 ml water, 13 mg ortho-dianisidine, and 13 mg B-napthyl acid
phosphate).
Waveguide Preparation
Polystyrene waveguides (Research International, Monroe, WA) were sonicated
for 30 seconds in a sonicating bath (Ultrasonic Cleaner Model 250, E/MC Corp.,
Hauppaugh, NY) containing isopropanol, and dipped into deionized water to rinse. The
waveguides were allowed to air dry in a waveguide stand. The distal tips of the
waveguides were painted with flat, black model paint (Testors, Rockford, IL) to provide a
light dump. Paint was allowed to dry. The waveguides were then inserted into cut glass
capillary tubes and incubated at 4º C for 12 hours with a 100 µg/ml solution of
streptavidin. Waveguides were rinsed with PBST. Biotin-labeled anti-M. tuberculosis
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antibody was used as the capture antibody (Biodesign International). Capture antibody
at 100 µg/ml in PBS was added to and incubated with waveguides for 30 min. Capture
antibody solution was then replaced with fresh capture antibody solution and incubated
for another 30 min before using in an assay. Waveguides were dipped in PBS ten times
before insertion into coupons to remove excess biotin labeled antibody. Figure 1 shows a
waveguide.

Figure 1: Waveguide.
Analyte 2000
The Analyte 2000 (Research International, Monroe, WA) is one of two biosensors
used in this study. This biosensor is a small, portable, manual mode, fiber optic
biosensor that has been used to rapidly detect bacteria. A sandwich immunoassay is the
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basis for the biosensor’s detection platform. This biosensor uses polystyrene waveguides
coated with streptavidin (a protein produced by Streptomyces avidinii which has four
binding sites for biotin). A biotin labeled polyclonal capture antibody is then incubated
on the waveguides. The sample of interest is applied to the waveguides and allowed to
incubate. A Cyanine-5 (Cy-5) labeled detection polyclonal antibody is then incubated on
the waveguide.
The Analyte 2000 is an evanescent wave fiber optic biosensor that has a laser that
emits a 635 nm beam of light. The laser excites the fluorescent molecule cyanine 5
(Cy5), causing the Cy5 to emit light at wavelengths above 670 nm. The emitted light is
recorded in picoAmps by the biosensor. The signal increases in proportion to the amount
of target bacteria present on a waveguide. This biosensor has been used to detect
Staphylococcal enterotoxin B, ricin, Clostridium botulinum toxin A, E. coli
lipopolysaccharide endotoxin, Bacillus anthracis, Escherichia coli O157:H7, Salmonella
typhimurium, Vaccinia virus, Francisella tularensis, Cryptosporidium parvum, matrices
in apple juice, ground beef, other foods, drinking water, seawater and human clinical
specimens (21, 22, 52). Research International was the source of all biosensor
accessories including cuvettes, software, adaptors, and waveguides. The Analyte 2000 is
shown in Figure 2.
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Figure 2: Analyte 2000.
Analyte 2000 Assay
The Analyte 2000 was initially used to determine the concentration of prepared
Freund’s adjuvant of M. tuberculosis that could be detected when anti-M. tuberculosis
antibody was used as capture and detection molecules (Figure 3). Waveguides adsorbed
with streptavidin and biotin labeled anti-M. tuberculosis antibody were inserted into
cuvettes and locked into place. Waveguides were rinsed with 1 ml PBST. A volume of
0.5 ml of sample was applied to the waveguide and incubated for 5 min. Another 0.5 ml
volume of sample was applied to the waveguide and incubated for 5 more min. The
waveguide was then rinsed with 1 ml PBST. Detection antibody (Cy5 labeled anti-M.
tuberculosis at 10 µg/ml) at a volume of 0.2 ml was then incubated on each waveguide
for 5 min. Waveguides were rinsed two times with PBST, and the laser was activated.
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The signal was recorded in picoamperes (pA). Readings were then taken at 10 seconds.
Four baselines were run with PBS, and then samples were run through the Analyte.
Samples of Freund’s adjuvant and live attenuated M. tuberculosis samples were run
through the Analyte 2000. These were always separate assays, but the concentrations for
Freund’s adjuvant complete were approximately 105, 106, 107 and 108 CFU/ml. The
concentrations for live attenuated M. tuberculosis were 106, 107 and 108 CFU/ml.
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Figure 3: Assay format using biosensor waveguide.
RAPTOR
The RAPTOR (Research International, Monroe, WA) is one of two biosensors
used in this study. This biosensor is a small, portable, automated, fiber optic biosensor
that has been used to rapidly detect bacteria. A sandwich immunoassay is the basis for
the biosensor’s detection platform. This biosensor uses polystyrene waveguides coated
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with streptavidin (a protein produced by Streptomyces avidinii which has four binding
sites for biotin). A biotin labeled polyclonal capture antibody is then incubated on the
waveguides. The sample of interest is applied to the waveguides and allowed to incubate.
A Cyanine-5 (Cy-5) labeled detection polyclonal antibody is then incubated on the
waveguide.
The RAPTOR is an evanescent wave fiber optic biosensor that has a laser that
emits a 635 nm beam of light. The laser excites the fluorescent molecule cyanine 5
(Cy5), causing the Cy5 to emit light at wavelengths above 670 nm. The emitted light is
recorded in picoAmps by the biosensor. The signal increases in proportion to the amount
of target bacteria present on a waveguide. This biosensor has been used to detect
Staphylococcal enterotoxin B, ricin, Clostridium botulinum toxin A, E. coli
lipopolysaccharide endotoxin, Bacillus anthracis, Escherichia coli O157:H7, Salmonella
typhimurium, Vaccinia virus, Francisella tularensis and Cryptosporidium parvum in
complex matrices including apple juice, ground beef, other foods, drinking water,
seawater and human clinical specimens (52). Research International was the source of all
biosensor accessories including cuvettes, software, adaptors, and waveguides. The
RAPTOR is shown in Figure 4.
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Figure 4: RAPTOR.
RAPTOR Assay
The RAPTOR fiber optic biosensor is the size of a car battery. Waveguides
coated with anti-M. tuberculosis antibody were inserted into a RAPTOR coupon, glued,
and the coupon was sealed with tape. The RAPTOR coupon is shown in Figure 5. The
RAPTOR was programmed to run automatically using the following sample recipe.
Samples put into the RAPTOR’s sample port were automatically pumped over the
waveguides and incubated. Sample fluid was automatically refreshed every 2.5 min for a
total of 10 min of sample incubation. Samples were then automatically rinsed with
PBST. Cy5 labeled polyclonal detection antibody at 2.5 µg/ml in blocking buffer was
then automatically pumped over the waveguides and incubated for 5 min. Detection
antibody was then sent back to detection antibody supply and waveguides were then
rinsed two times with approximately 1 ml of PBST. The RAPTOR laser was turned on,
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and the resulting pA signal was logged into a data file. The same automated assay was
used to test both live attenuated M. tuberculosis suspended in PBST and as well as lung
tissue seeded with M. tuberculosis. Five samples containing only PBST were run to
calculate the LOD.

Figure 5: RAPTOR coupon.
Live Attenuated M. tuberculosis Preparation for RAPTOR
Preparation was the same as Analyte 2000 protocols. Five PBST baselines served
as blanks. The Cy5 labeled detection antibody concentration used was 2.5 µg/ml.
Lung Preparation
A donated tuberculosis-free, human lung was obtained from Tissue
Transformation Technologies (Edison, NJ) of a 56 year old Caucasian female with a
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weight of 139 lbs with no history of HIV, Hepatitis B, Hepatitis C, respiratory disease,
neurological problems, cancer, diabetes, hypertension, gastrointestinal tract problems,
kidney disease, or drug use. Additional donor information included A+ blood type and
liver disease with cirrhosis. The lung was removed from a -80º C freezer in which it was
stored, left out at 24º C for 18 hours, and transported to the Hillsborough County Medical
Examiner’s Office in a styrofoam cooler. The lung was sectioned under aseptic
conditions under the supervision of Dr. Jacqueline Lee, Associate Medical Examiner,
Hillsborough County, Florida. The cutting board was covered with a sterile homicide
sheet and by a sterile surgical gown. Knife, scalpels and surrounding area were sterilized
with 75% isopropanol. The lung was sectioned while placed on the gown.

The three

different lobes of right lung were separated into 50 ml conical tubes and labeled to
signify upper lobe, middle lobe or lower lobe. Approximately 20 g of tissue was placed
into each tube. The samples were transported back to the University of South Florida and
stored in the -80º C freezer for future use.
Live Attenuated M. tuberculosis Preparation for Use in Seeding into Lung Tissue for
Use in the RAPTOR
Live attenuated M. tuberculosis for use in lung tissue RAPTOR assays was
prepared as described for previous procedures but, before seeding into lung tissue, was
homogenized in a glass homogenizer with PBST for approximately 2-5 minutes to break
up clumping that had been shown to clog the RAPTOR. Direct counts were performed.
One ml aliquots were placed in the -80º C freezer for future use in assays.
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RAPTOR Assays with M. tuberculosis Seeded into Lung Tissue
Samples of lung were defrosted and cut into smaller pieces of four grams each
with scissors and aliquoted. Attenuated M. tuberculosis at specific concentrations were
added to 50 ml tissue grinders (Fisher, Houston, TX), along with PBST and lung tissue.
The samples were ground for two minutes and allowed to sit for five minutes. Pieces of
lung tissue were removed with forceps. The suspension in PBST was sent through the
sensor, after being homogenized in a glass homogenizer.
Specificity Testing Using the RAPTOR
The automated RAPTOR assay previously described was followed. Waveguide
preparation, antibody concentrations and bacteria preparations were the same as
previously described. However, four PBST samples serving as baselines were used to
calculate the LOD. Bacteria were diluted in PBS or, in the case of Mycobacterium
species, were diluted in PBST. When bacteria other than M. tuberculosis were tested,
concentrations of 106, 107 and 108 CFU/ml were used as samples, followed by a sample
of M. tuberculosis at 108 CFU/ml. Each experiment consisted of the serial dilutions of
only one type of bacteria, followed by M. tuberculosis at 108 CFU/ml. The various
bacteria tested for cross reactivity with antibody to M. tuberculosis were E. coli K-12,
Haemophilus influenzae, Streptococcus agalactiae, Klebsiella pneumoniae,
Streptococcus pneumoniae, Staphylococcus aureus, Mycobacterium rhodochrous,
Proteus mirabilis, Pseudomonas aeruginosa, Mycobacterium smegmatis, Candida
albicans, Mycobacterium gordonae and Mycobacterium intracellulare.
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Analyte 2000 and RAPTOR Calculations
The pA signal was recorded for all baselines and samples at the 10 second
reading. The pA value for each reading was subtracted from the subsequent reading; the
calculated value was designated as the signal change (pA) from the previous reading.
The limit of detection (LOD) was calculated as the mean signal change (pA) from the
previous reading for baselines (mean baseline value) plus three times the standard
deviation (SD). A positive signal was designated as the value of signal change from
previous reading that is > LOD.
Cleaning of the Analyte 2000 and RAPTOR
The Analyte 2000 was disassembled after each assay. Lysol was used to first
soak, and then wash, the tubing and chambers. After rinsing with deionized water, the
tubing and chambers were allowed to dry. At the end of a RAPTOR assay, the coupon
used during the assay testing was removed. A cleaning coupon (a coupon containing
clean waveguides without any antibody or bacteria) was inserted. Three cleaning cycles
were programmed into the RAPTOR. For cycle one, the wash container had Lysol
added. For cycles two and three, deionized water was used for rinsing.
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Results
Freund’s Adjuvant Complete Testing
Rapid detection of M. tuberculosis at autopsy using lung tissue from decedents
would be a helpful diagnostic tool. The objective of this study was to develop a
biosensor assay to detect M. tuberculosis in decedent lung tissue. Initially, treated
Freund’s adjuvant complete was used as a surrogate for M. tuberculosis, since it was nonviable, and its use involved minimum risk.
An ELISA was performed using Freund’s adjuvant complete in order to
determine the portion of adjuvant that was bound by the anti-M. tuberculosis antibody
(Table 1, Figure 6). When the Freund’s adjuvant complete was centrifuged, two layers
formed: a yellow oil layer on the top and a white pellet at the bottom of the tube. The
white pellet was washed twice with PBST and resuspended in 1 ml of PBST. Serial
dilutions, adsorbed to wells of 96 well plates, of the oil layer, resuspended pellet and
intact adjuvant were tested using ELISA. The reactivity of the anti-M. tuberculosis
antibody to Freund’s adjuvant complete, the oil layer or to the pellet layer was
determined by calculating the signal over background. The signal over background was
calculated by dividing the relative fluorescence units produced in each well by the RFU
of PBS, the negative control (background). The mean signal over background was
calculated from two ELISAs performed with Freund’s adjuvant complete to test the
reactivity with antibody to M. tuberculosis. Antibody concentrations for all wells were
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10 µg/ml in PBS. Serial dilutions were performed for the oil layer, pellet and Freund’s
adjuvant complete from 100 to 10-6.
Table 1: Freund’s adjuvant complete reactivity with M. tuberculosis antibody.
Freund’s adjuvant
complete concentration
(µg/ml)
Oil layer
1000
6.8
100
2.6
10
4.3
1
2.2
0.1
2.3
0.01
2.0
0.001
1.7
0
1.0
a
Mean signal over background.

ELISA readingsa
Pellet
Freund’s adjuvant complete
8.0
4.2
6.9
3.3
3.3
4.2
2.0
1.8
1.7
1.9
0.8
1.3
0.8
1.3
1.0
1.0

14.0

Oil layer
Pellet
Adjuvant

Signal Over Background

12.0
10.0
8.0
6.0
4.0
2.0
0.0
1000

100

10

1

0.1

0.01

0.001

0

Oil Layer, Pellet and Adjuvant Concentration (µg/ml)

Figure 6: ELISA results of anti-M. tuberculosis antibody reactivity to Freund’s adjuvant
complete.
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The reactivity of anti-M. tuberculosis antibody to Freund’s adjuvant complete oil
layer, pellet, or intact adjuvant was tested. The ELISA demonstrated that the anti-M.
tuberculosis antibody showed greatest reactivity to the resuspended pellet. The antibody
also bound to the oil layer and bound only slightly to the Freund’s adjuvant complete.
Since the anti-M. tuberculosis antibody was most reactive to the pellet, the pellet was
used for further biosensor testing.
Analyte 2000 Testing with Pellet from Freund’s Adjuvant Complete
The Analyte 2000 was initially used for biosensor detection of the pellet from
Freund’s adjuvant complete. Samples containing only PBS were used to record
baselines. Representative change from previous reading was calculated of data from an
Analyte 2000 assay showing detection of pellet from Freund’s adjuvant complete using
anti-M. tuberculosis antibody for capture and detection (Table 2).
Table 2: Analyte 2000 assay with Freund’s adjuvant complete.
Channels
LODb

1
30.93

Baselines
B2
B3
B4

0.5
15.9
4.6

Analyte 2000 readingsa
2
3
71.30
41.58
42.4
20.5
12.8

Pellet concentration
(µg/ml)
0.1
32.4c
16.8
1
46.3
51.6
10
485.7
304.0
100
1656.1
1136.8
a
Calculated change from previous reading (pA).
b
Limit of detection.
c
Boldfaced numbers indicate positive result.
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4
47.43

28.0
15.3
15.2

30.3
12.7
19.2

14.8
41.2
228.9
768.2

12.6
60.1
248.5
1232.5

Baseline 2 (B2) through Baseline 4 (B4) consist of the change from previous
reading of PBS. Biotin labeled capture antibody was used at a concentration of 100
µg/ml. Cy5 labeled detection antibody was suspended in blocking buffer at a
concentration of 10 µg/ml. The change from previous readings that are positive (>LOD)
are in bold type in Table 2. Concentration of pellet was based on the 1 mg/ml
concentration of M. tuberculosis in Freund’s adjuvant complete.
One of the Analyte 2000 biosensor four channels was positive at 0.1 µg/ml. Two
out of four channels were positive at 1 µg/ml. All channels were positive when the
concentration of pellet was 10 µg/ml and 100 µg/ml. The exact concentration of cells in
the resuspended pellet could not be determined by directly counting cells using a
hemocytometer. The oil carried over from the complete adjuvant interfered with the
visualization of cells. The assay was repeated two more times, yielding similar results.
Three Analyte 2000 assays were performed. Table 3 shows the number of
channels that gave positive results of the three Analyte 2000 assays testing with M.
tuberculosis pellet from Freund’s adjuvant complete. Concentration is based on the 1
mg/ml of M. tuberculosis in the Freund’s adjuvant complete.
Table 3: Results of three Analyte 2000 assays with Freund’s adjuvant complete.
Pellet concentration
Number of positive channelsa
(µg/ml)
Assay 1
Assay 2
Assay 3
0.1
1/4
0/4
1/4
1
2/4
2/4
2/4
10
4/4
4/4
4/4
100
4/4
4/4
4/4
a
Number of positive channels out of the total possible positive channels in an assay.
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Analyte 2000 Testing with Live Attenuated M. tuberculosis
The anti-M. tuberculosis was capable of capturing and detecting the killed M.
tuberculosis found in Freund’s adjuvant complete using the Analyte 2000 biosensor
assay. These results suggested that the antibody would also work well in capturing and
detecting live M. tuberculosis. Samples containing serial dilutions of viable attenuated
M. tuberculosis (ATCC 25177) were tested using the Analyte 2000 biosensor. The
protocol followed was identical to the Analyte 2000 assays previously described. It was
possible to directly count the live attenuated M. tuberculosis prior to performing the
assay. Representative change from previous reading was calculated of data from an
Analyte 2000 assay for detection of live attenuated M. tuberculosis suspended in PBST.
The change from previous readings that are positive (>LOD) are in bold type. Assay
results are shown in Table 4.
Table 4: Analyte 2000 assay with live attenuated M. tuberculosis.
Channels
LODb

1
22.5

Baselines
B2
B3
B4

13.4
9.9
4.6

Analyte 2000 readingsa
2
3
111.9
65.0
47.9
-17.2
-2.0

4
61.1

-31.1
15.5
-30.6

25.4
-3.1
-10.9

M. tuberculosis
concentration
(CFU/ml)
50.8c
134.3
154.5
2.08 x 106
7
2.08 x 10
1669.3
1451.3
1446.8
2.08 x 108
3234.0
2612.5
2893.0
a
Calculated change from previous reading (pA).
b
Limit of detection.
c
Boldfaced numbers indicate positive result.

134.8
310.1
1461.7
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All channels were positive at 2.08 x 106, 2.08 x 107 and 2.08 x 108 CFU/ml. The
assay was repeated. Table 5 shows the number of channels that tested positive in the two
Analyte 2000 biosensor assays for the detection of live attenuated M. tuberculosis.
Table 5: Results of two Analyte 2000 assays with live attenuated M. tuberculosis.
M. tuberculosis
concentration
Number of positive channelsa
(CFU/ml)
Assay 1
Assay 2
106
4/4
3/4
107
4/4
4/4
108
4/4
4/4
a
Number of positive channels out of the total possible positive channels in an assay.

RAPTOR Testing with Live Attenuated M. tuberculosis
A RAPTOR biosensor assay for the detection of M. tuberculosis was developed,
so that a rapid, automated, user friendly assay could ultimately be used during autopsy.
PBST, instead of PBS, samples were used to take baseline readings. The biotin labeled
M. tuberculosis capture antibody was kept at a concentration of 100 µg/ml. In initial
RAPTOR assays, concentrations of 5 and 10 µg/ml for the Cy5 labeled detection
antibody and 100 µg/ml for capture antibody were tested. These concentrations resulted
in extremely high LODs (data not shown). Table 6 shows a representative assay using
the concentration of 50 µg/ml for capture antibody and 2.5 µg/ml for detection antibody.
Four PBST samples served to record baseline readings. The RAPTOR was programmed
to run automatically as previously described. Representative change from previous
reading was calculated of data from a RAPTOR assay for detection of live attenuated M.
tuberculosis suspended in PBST. The change from previous readings that are positive (>
LOD) are in bold type.
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Table 6: RAPTOR assay with live attenuated M. tuberculosis.
Channels
LODb

1
24.63

Baselines
B2
B3
B4
B5

13.5
17.1
19.8
17.1

RAPTOR readingsa
2
3
44.76
32.71
38.6
33.0
30.9
36.0

M. tuberculosis
concentration
(CFU/ml)
22.9
42.8
2.08 x 104
2.08 x 105
44.2c
55.6
119.0
111.8
2.08 x 106
2.08 x 107
185.1
214.2
2.08 x 108
302.5
258.5
a
Calculated change from previous reading (pA).
b
Limit of detection.
c
Boldfaced numbers indicate positive result.

4
38.60

20.8
12.0
20.8
21.9

17.7
16.7
25.1
7.3

21.3
25.6
60.9
99.9
146.3

27.7
31.4
109.1
177.6
241.4

Channels 1 and 2 were positive at 2.08 x 105 CFU/ml. All channels were positive
at 2.08 x 106, 2.08 x 107 and 2.08 x 108 CFU/ml. The assay was repeated eighteen more
times. Table 7 shows the number of channels that tested positive in the seven RAPTOR
biosensor assays for the detection of live attenuated M. tuberculosis.
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Table 7: Results of nineteen RAPTOR assays with live attenuated M. tuberculosis.
M. tuberculosis
concentration
(CFU/ml)
106
107
108

Number of positive channelsa
Assay 1
Assay 2
Assay 3
4/4
4/4
0/4
4/4
4/4
2/4
4/4
4/4
4/4

Assay 4
4/4
4/4
4/4

106
107
108

Assay 5
4/4
4/4
4/4

Assay 6
0/4
4/4
4/4

Assay 7
3/4
4/4
4/4

Assay 8
2/4
4/4
4/4

106
107
108

Assay 9
0/4
4/4
4/4

Assay 10
4/4
4/4
4/4

Assay 11
3/4
2/4
4/4

Assay 12
2/4
2/4
3/4

106
107
108

Assay 13
4/4
4/4
4/4

Assay 14
4/4
4/4
4/4

Assay 15
4/4
4/4
4/4

Assay 16
4/4
4/4
4/4

Assay 17
Assay 18
Assay 19
106
4/4
4/4
3/4
107
4/4
4/4
2/4
108
4/4
4/4
4/4
a
Number of positive channels out of the total possible positive channels in an assay.

RAPTOR Testing with Live Attenuated M. tuberculosis Seeded into Decedent Lung
Tissue
A biosensor assay for the detection of live attenuated M. tuberculosis in PBST
seeded into decedent lung tissue was performed on the RAPTOR. The goal was to
develop a rapid, automatic assay for the detection of M. tuberculosis in lung tissue.
Sample preparation of lung tissue was first developed. Various techniques were tried,
using a modified lung preparation procedure of the Hillsborough County Medical
Examiner’s Office and the Florida Department of Health, Mycobacteriology Laboratory
as a foundation. Live attenuated M. tuberculosis at 108 CFU/ml in PBST was serial
diluted in PBST to make the concentrations of 106, 107 and 108 CFU/ml in separate tissue
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grinders, with a final volume of approximately four ml in each grinder. Approximately
four grams of lung tissue pieces from the upper lobe were added to tissue grinders. M.
tuberculosis was ground with lung pieces in the grinders for two minutes. The samples
were incubated at 25º C for approximately five minutes. Using long forceps, each clump
of tissue was removed, while being rinsed and shaken into the liquid. The remaining
liquid was then tested using the RAPTOR. The concentrations of capture and detection
antibodies were kept at 50 µg/ml and 2.5 µg/ml, respectively. The results of a
representative RAPTOR assay are shown below in Table 8. Representative change from
previous reading was calculated of data from a RAPTOR assay for detection of live
attenuated M. tuberculosis suspended in PBST seeded into decedent lung tissue. The
change from previous readings that are positive (> LOD) are in bold type.
Table 8: RAPTOR assay with live attenuated M. tuberculosis in decedent lung tissue.
Channels
LODb

1
98.44

Baselines
B2
B3
B4

79.0
59.8
56.7

RAPTOR readingsa
2
3
108.72
56.58
91.2
78.3
76.7

M. tuberculosis
concentration
(CFU/ml)
1.6 x 106
136.7c
131.8
7
1.6 x 10
234.9
298.8
1.6 x 108
245.9
609.2
a
Calculated change from previous reading (pA).
b
Limit of detection.
c
Boldfaced numbers indicate positive result.

4
55.57

42.1
23.0
34.3

39.2
36.6
29.8

74.0
135.3
210.9

79.0
131.0
118.6

All channels were positive at 1.6 x 106, 1.6 x 107 and 1.6 x 108 CFU/ml. The
assay was repeated six more times. Table 9 shows the number of channels that tested
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positive in the seven RAPTOR biosensor assays for the detection of live attenuated M.
tuberculosis seeded into decedent lung tissue.
Table 9: Results of seven RAPTOR assays with live attenuated M. tuberculosis in
decedent lung tissue.
M. tuberculosis
concentration
(CFU/ml)
106
107
108

Number of positive channelsa
Assay 1
Assay 2
Assay 3
4/4
0/4
0/4
4/4
3/4
3/4
4/4
4/4
4/4

Assay 4
0/4
4/4
4/4

Assay 5
Assay 6
Assay 7
2/4
0/4
0/4
106
107
4/4
3/4
3/4
108
4/4
4/4
4/4
a
Number of positive channels out of the total possible positive channels in an assay.

Based on these seven assays, the M. tuberculosis RAPTOR assay could detect M.
tuberculosis when it was present in lung tissue. When the bacteria were present at 106
CFU/g, the RAPTOR assay resulted in positive signals 21% of the time. When M.
tuberculosis was at a concentration of 107 CFU/g, the RAPTOR assay detected M.
tuberculosis in 86% of the channels, and when present at a concentration of 108 CFU/g,
M. tuberculosis was detected in 100% of channels.
ELISA Testing with M. tuberculosis Antibody
ELISAs were used to determine the anti-M. tuberculosis antibody’s reactivity to
bacteria other than M. tuberculosis. In preparation for specificity studies, a direct ELISA
using different concentrations of anti-M. tuberculosis antibody was run using a single
concentration for M. tuberculosis. Triplicates were run at each antibody concentration.
M. tuberculosis at a concentration of 1.2 x 108 CFU/ml was adsorbed to all wells of the
ELISA plate. Anti-M. tuberculosis antibody was diluted in 1:2 dilutions using blocking
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buffer. Negative control (background) wells containing only blocking buffer were also
tested. The results are shown in Table 10 and Figure 7. The mean signal over
background was calculated for serial dilutions of M. tuberculosis antibody binding to live
attenuated M. tuberculosis at 1.2 x 108 CFU/ml.
Table 10: M. tuberculosis antibody reactivity with M. tuberculosis.
M. tuberculosis
antibody concentration
ELISA readingsa
(µg/ml)
1/100
12.57
1/200
12.68
1/400
12.68
1/800
11.64
1/1600
10.51
1/3200
8.4
1/6400
5.48
a
Mean signal over background.
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Signal Over Background

12
10
8
6
4
2
0
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Anti-M. tuberculosis Antibody Concentration (µg/ml)

Figure 7: ELISA results of anti-M. tuberculosis antibody reactivity to M. tuberculosis.
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The mean signal over background was calculated for serial dilutions of anti-M.
tuberculosis antibody binding to viable M. tuberculosis adsorbed to wells at a
concentration of 1.2 x 108 CFU/ml. Error bars represent one standard deviation from
triplicate readings. The ELISA showed a signal to background value of >12 when the
concentration of anti-M. tuberculosis antibody was 25-100 µg/ml. Based on these results,
the 25 µg/ml antibody concentration was used in ELISA to detect different
concentrations of M. tuberculosis. The results are shown in Table 11 and Figure 8.
Triplicates were run at each concentration of M. tuberculosis. The mean signal over
background was calculated for the reactivity of M. tuberculosis antibody to various
concentrations of attenuated M. tuberculosis.
Table 11: Anti-M. tuberculosis antibody reactivity at various concentrations of M.
tuberculosis.
M. tuberculosis
Concentration
ELISA readingsa
(CFU/ml)
0
1
1.2 x 102
1.04
1.2 x 103
1.55
1.2 x 104
2.17
1.2 x 105
5.02
1.2 x 106
8
1.2 x 107
9.26
1.2 x 108
10.05
a
Mean signal over background.
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M. tuberculosis ATCC 25177 (Log CFU/ml or 0 for no cells)

Figure 8: ELISA results of anti-M. tuberculosis antibody reactivity at various
concentrations of M. tuberculosis.
The mean signal over background was calculated for the detection of M.
tuberculosis at various concentrations. Error bars represent one standard deviation from
triplicate readings. Mean signal over background values were higher than 2.0 when the
M. tuberculosis concentration was at or higher than 104 CFU/ml. Signal over background
values were greater than 8.0 when the M. tuberculosis concentration was at or higher than
106 CFU/ml.
The same direct ELISA format was used to test for cross reactivity of the anti-M.
tuberculosis antibody to different microorganisms. The species tested were Escherichia
coli K-12, Haemophilus influenzae, Streptococcus agalactiae, Klebsiella pneumoniae,
Streptococcus pneumoniae, Staphylococcus aureus, Mycobacterium rhodochrous,
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Proteus mirabilis, Pseudomonas aeruginosa, Mycobacterium smegmatis, Candida
albicans, Mycobacterium gordonae and Mycobacterium intracellulare. These various
microorganisms were tested, as they can be present during a M. tuberculosis infection or
mimic mycobacterial infection of the lungs.
ELISAs were performed using 96-well plates. Cross reactivity to all bacteria was
tested in triplicate wells per serial dilution. M. tuberculosis ATCC 25177 was included
as a positive control for every plate tested. Therefore, only nine columns per plate were
available for testing other bacteria. Several plates were used in ELISAs, so that all
organisms previously listed could be tested. Bacteria were directly adsorbed to wells of
ELISA plates, and the anti-M. tuberculosis antibody was used at a concentration of 2.5
µg/ml as previously described. Results are shown in Figures 9 through 13.
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Attenuated M.
tuberculosis
1.2x108
CFU/ml
Escherichia
coli K-12
2.0x108
CFU/ml
Haemophilus
influenzae
2.4x108
CFU/ml
Streptococcus
agalactiae
2.0x108
CFU/ml

Figure 9: ELISA results of the reactivity of M. tuberculosis antibody with attenuated M.
tuberculosis, Escherichia coli K-12, Haemophilus influenzae and Streptococcus
agalactiae.
The log CFU/ml is shown for the cell concentration. However, the CFU/ml was
slightly different for each bacterium. The actual concentration (in CFU/ml) is shown in
the legend for each bacterium. M. tuberculosis mean signal over background was greater
than 2.0, when cell concentration was 104 and greater CFU/ml. The mean signal over
background was greater than 6.0, when cell concentration was 106, 107 and 108 CFU/ml.
The mean signal over background value remained below 2.0, when the concentration of
Escherichia coli K-12 cells being tested was below 106 CFU/ml. The mean signal over
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background never increased above 6.0, even when high concentrations (107 - 108

Signal Over Background

CFU/ml) of cells were tested. This was also true for H. influenzae and S. agalactiae.
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Figure 10: ELISA results of the reactivity of M. tuberculosis antibody with attenuated
M. tuberculosis, Klebsiella pneumoniae, Streptococcus pneumoniae and Staphylococcus
aureus.
The log CFU/ml is shown for the cell concentration. However, the CFU/ml was
slightly different for each bacterium. The actual concentration (in CFU/ml) is shown in
the legend for each bacterium. M. tuberculosis mean signal over background was greater
than 2.0, when cell concentration was 102, 104, 105, 106, 107 and 108 CFU/ml. The mean
signal over background was greater than 6.0, when cell concentration was 106, 107 and
108 CFU/ml. The mean signal over background value remained below 2.0, when the
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concentration of Klebsiella pneumoniae cells tested was below 107 CFU/ml. The mean
signal over background value remained below 6.0, when the concentration of
Streptococcus pneumoniae cells tested was below 107 CFU/ml. The mean signal over
background value remained below 4.0, when the concentration of Staphylococcus aureus
cells tested was below 106 CFU/ml.
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Figure 11: ELISA results of the reactivity of M. tuberculosis antibody with attenuated
M. tuberculosis, Mycobacterium rhodochrous, Proteus mirabilis and Pseudomonas
aeruginosa.
The log CFU/ml is shown for the cell concentration. However, the CFU/ml was
slightly different for each bacterium. The actual concentration (in CFU/ml) is shown in
the legend for each bacterium. M. tuberculosis mean signal over background was greater
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than 2.0, when cell concentration was 103 and greater CFU/ml. The mean signal over
background value remained below 2.0 for all concentrations of Mycobacterium
rhodochrous. The mean signal over background never increased above 6.0, even when
high concentrations (107 - 108 CFU/ml) of cells were tested of Proteus mirabilis. The
mean signal over background value was greater than 6.0, when cell concentration was 107
and 108 CFU/ml for Pseudomonas aeruginosa.
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Figure 12: ELISA results of the reactivity of M. tuberculosis antibody with attenuated
M. tuberculosis, Mycobacterium smegmatis, Candida albicans and Mycobacterium
gordonae.
The log CFU/ml is shown for the cell concentration. However, the CFU/ml was
slightly different for each microorganism. The actual concentration (in CFU/ml) is
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shown in the legend for each microbe. M. tuberculosis mean signal over background was
greater than 2.0, when cell concentration was 105 CFU/ml or higher. The mean signal
over background was greater than 6.0, when cell concentration was 107 CFU/ml or
higher. The mean signal over background value remained below 2.0, when the
concentration of Mycobacterium smegmatis cells tested was less than 107 CFU/ml. The
mean signal over background never increased above 6.0, even when high concentrations
(107 - 108 CFU/ml) of Candida albicans were tested. The mean signal over background
value remained below 4.0, when the concentration of Mycobacterium gordonae tested
was below 107 CFU/ml.
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Figure 13: ELISA results of the reactivity of M. tuberculosis antibody with attenuated
M. tuberculosis and Mycobacterium intracellulare.
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The log CFU/ml is shown for the cell concentration. The actual concentration (in
CFU/ml) is shown in the legend for each bacterium. M. tuberculosis mean signal over
background was greater than 2.0, when cell concentration was 105 CFU/ml or higher.
The mean signal over background never increased above 6.0, even when high
concentrations (107 – 108 CFU/ml) of Mycobacterium intracellulare were tested. Based
on the cross reactivity of the anti-M. tuberculosis antibody to these organisms, cross
reactivity studies in the RAPTOR were performed.
M. tuberculosis Antibody Specificity Studies Using the RAPTOR
RAPTOR assay specificity studies were performed using the anti-M. tuberculosis
antibody as the capture and detection molecule at 50 µg/ml and at 2.5 µg/ml,
respectively, as previously described. Each experiment consisted of first testing serial
dilutions containing a specific bacterium other than M. tuberculosis. In order to verify
that the RAPTOR assay was operating correctly, after all dilutions of the bacterium were
assayed, a high concentration (108 CFU/ml) of M. tuberculosis ATCC 25177 was then
assayed using the same coupon. The M. tuberculosis assay resulted in a high increase in
the change from previous signal. The results are shown in Tables 12a through 12m and
Table 13. In Tables 12a through 12m, the change from previous readings that are
positive (> LOD) are in bold type.
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Table 12a: RAPTOR assay to test anti-M. tuberculosis antibody cross reactivity to
Staphylococcus aureus.
RAPTOR readingsa
2
3
75.5
48.1

Channels
LODb

1
142.5

Baselines
B2
B3
B4

79.6
37.4
82.7

44.8
59.8
45.3

36.9
26.1
32.3

61.6
19.4
24.5

Staphylococcus
aureus
concentration
(CFU/ml)
2.4 x 106
2.4 x 107
2.4 x 108

3.1
66.0
54.5

12.9
51.5
57.7

19.2
17.7
43.2

23.0
23.5
24.0

169.8

204.8

M. tuberculosis
concentration
(CFU/ml)
1.2 x 108
167.4c
227.7
a
Calculated change from previous reading (pA).
b
Limit of detection.
c
Boldfaced numbers indicate positive result.
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4
104.3

Table 12b: RAPTOR assay to test anti-M. tuberculosis antibody cross reactivity to
Streptococcus pneumoniae.
RAPTOR readingsa
2
3
104.4
108.0

Channels
LODb

1
62.0

Baselines
B2
B3
B4

49.4
36.4
40.0

61.8
49.0
22.6

65.1
32.3
21.3

37.0
16.3
51.7

Streptococcus
pneumoniae
concentration
(CFU/ml)
1.6 x 106
1.6 x 107
1.6 x 108

24.5
50.9
42.1

38.1
29.9
28.8

36.5
12.5
23.9

28.8
50.7
-2.6

166.6

176.6

M. tuberculosis
concentration
(CFU/ml)
1.2 x 108
252.1c
269.4
a
Calculated change from previous reading (pA).
b
Limit of detection.
c
Boldfaced numbers indicate positive result.
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4
88.4

Table 12c: RAPTOR assay to test anti-M. tuberculosis antibody cross reactivity to
Escherichia coli K-12.
RAPTOR readingsa
2
3
109.5
102.1

Channels
LODb

1
61.8

Baselines
B2
B3
B4

22.4
41.6
34.3

75.0
91.0
72.7

68.2
33.8
41.1

26.1
64.8
33.4

Escherichia
coli K-12
concentration
(CFU/ml)
2.0 x 106
2.0 x 107
2.0 x 108

12.4
28.6
14.1

46.3
63.9
61.3

26.6
22.9
33.8

37.1
42.8
30.3

223.4

245.0

M. tuberculosis
concentration
(CFU/ml)
1.2 x 108
193.8c
255.9
a
Calculated change from previous reading (pA).
b
Limit of detection.
c
Boldfaced numbers indicate positive result.
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4
103.1

Table 12d: RAPTOR assay to test anti-M. tuberculosis antibody cross reactivity to
Haemophilus influenzae.
RAPTOR readingsa
2
3
115.7
66.3

Channels
LODb

1
77.5

Baselines
B2
B3
B4

64.4
58.3
51.4

74.7
33.0
42.2

43.2
22.9
38.0

46.4
45.0
47.0

Haemophilus
influenzae
concentration
(CFU/ml)
2.4 x 106
2.4 x 107
2.4 x 108

32.3
8.3
49.4

19.0
38.6
10.9

54.7
-3.1
49.4

21.4
34.0
37.6

182.7

222.5

M. tuberculosis
concentration
(CFU/ml)
1.2 x 108
253.6c
261.6
a
Calculated change from previous reading (pA).
b
Limit of detection.
c
Boldfaced numbers indicate positive result.
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4
49.2

Table 12e: RAPTOR assay to test anti-M. tuberculosis antibody cross reactivity to
Klebsiella pneumoniae.
RAPTOR readingsa
2
3
66.8
90.3

Channels
LODb

1
67.2

Baselines
B2
B3
B4

43.7
53.0
38.4

55.1
54.1
45.9

34.9
48.4
9.4

35.5
42.8
34.5

Klebsiella
pneumoniae
concentration
(CFU/ml)
2.4 x 106
2.4 x 107
2.4 x 108

36.4
46.8
23.9

30.8
41.3
39.1

52.5
24.0
35.9

25.1
15.6
29.3

206.7

212.1

M. tuberculosis
concentration
(CFU/ml)
1.2 x 108
199.6c
282.2
a
Calculated change from previous reading (pA).
b
Limit of detection.
c
Boldfaced numbers indicate positive result.
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4
51.2

Table 12f: RAPTOR assay to test anti-M. tuberculosis antibody cross reactivity to
Streptococcus agalactiae.
RAPTOR readingsa
2
3
56.9
40.0

Channels
LODb

1
45.8

Baselines
B2
B3
B4

33.3
32.2
39.0

30.0
24.6
41.0

20.0
18.3
29.1

28.7
32.9
30.5

Streptococcus
agalactiae
concentration
(CFU/ml)
2.0 x 106
2.0 x 107
2.0 x 108

12.0
14.5
9.4

20.2
22.8
16.0

23.4
24.2
19.6

25.0
22.7
20.0

159.0

200.2

M. tuberculosis
concentration
(CFU/ml)
1.2 x 108
137.2c
250.1
a
Calculated change from previous reading (pA).
b
Limit of detection.
c
Boldfaced numbers indicate positive result.
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4
37.0

Table 12g: RAPTOR assay to test anti-M. tuberculosis antibody cross reactivity to
Pseudomonas aeruginosa.
RAPTOR readingsa
2
3
60.2
62.5

Channels
LODb

1
81.1

Baselines
B2
B3
B4

53.1
24.4
31.7

21.1
36.6
38.1

39.5
16.2
20.8

29.8
23.0
21.4

Pseudomonas
aeruginosa
concentration
(CFU/ml)
2.4 x 106
2.4 x 107
2.4 x 108

41.1
30.7
51.9

11.3
35.0
19.6

20.3
23.4
17.2

26.1
12.0
37.6

154.1

145.8

M. tuberculosis
concentration
(CFU/ml)
1.2 x 108
188.7c
173.0
a
Calculated change from previous reading (pA).
b
Limit of detection.
c
Boldfaced numbers indicate positive result.
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4
38.1

Table 12h: RAPTOR assay to test anti-M. tuberculosis antibody cross reactivity to
Candida albicans.
RAPTOR readingsa
2
3
117.0
111.5

Channels
LODb

1
78.7

Baselines
B2
B3
B4

68.1
72.2
65.5

98.4
86.0
79.3

56.8
62.4
22.9

50.0
45.2
40.0

Candida
albicans
concentration
(CFU/ml)
1.2 x 106
1.2 x 107
1.2 x 108

27.1
50.4
17.7

56.1
58.7
34.6

31.3
36.4
17.7

36.5
44.3
42.0

215.0

200.0

M. tuberculosis
concentration
(CFU/ml)
1.2 x 108
255.7c
297.6
a
Calculated change from previous reading (pA).
b
Limit of detection.
c
Boldfaced numbers indicate positive result.
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4
60.1

Table 12i: RAPTOR assay to test anti-M. tuberculosis antibody cross reactivity to
Mycobacterium rhodochrous.
RAPTOR readingsa
2
3
94.1
61.2

Channels
LODb

1
81.8

Baselines
B2
B3
B4

62.3
65.5
51.5

67.0
79.3
64.4

38.5
41.7
50.0

32.9
47.5
35.5

Mycobacterium
rhodochrous
concentration
(CFU/ml)
2.0 x 106
2.0 x 107
2.0 x 108

55.1
41.6
60.3

56.6
61.8
64.4

4.6
39.1
30.2

24.1
28.2
25.6

233.7

168.1

M. tuberculosis
concentration
(CFU/ml)
1.2 x 108
200.0c
195.3
a
Calculated change from previous reading (pA).
b
Limit of detection.
c
Boldfaced numbers indicate positive result.
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4
62.0

Table 12j: RAPTOR assay to test anti-M. tuberculosis antibody cross reactivity to
Proteus mirabilis.
RAPTOR readingsa
2
3
99.4
114.2

Channels
LODb

1
75.1

Baselines
B2
B3
B4

50.0
37.8
25.0

60.2
65.0
80.0

20.0
54.3
63.2

63.7
57.0
25.4

Proteus
mirabilis
concentration
(CFU/ml)
2.1 x 106
2.1 x 107
2.1 x 108

45.0
34.8
52.0

56.4
63.3
81.4

22.0
17.7
24.5

30.2
40.3
18.2

312.4

228.8

M. tuberculosis
concentration
(CFU/ml)
1.2 x 108
296.3c
430.1
a
Calculated change from previous reading (pA).
b
Limit of detection.
c
Boldfaced numbers indicate positive result.
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4
110.1

Table 12k: RAPTOR assay to test anti-M. tuberculosis antibody cross reactivity to
Mycobacterium smegmatis.
RAPTOR readingsa
2
3
76.9
103.9

Channels
LODb

1
129.1

Baselines
B2
B3
B4

81.6
80.0
46.3

65.4
53.6
57.1

64.6
53.1
28.6

46.0
8.4
24.5

Mycobacterium
smegmatis
concentration
(CFU/ml)
1.2 x 106
1.2 x 107
1.2 x 108

51.0
45.7
38.5

24.2
39.2
62.8

40.1
27.1
30.1

36.6
31.8
6.3

181.7

136.8

M. tuberculosis
concentration
(CFU/ml)
1.2 x 108
178.8c
179.2
a
Calculated change from previous reading (pA).
b
Limit of detection.
c
Boldfaced numbers indicate positive result.
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4
82.9

Table 12l: RAPTOR assay to test anti-M. tuberculosis antibody cross reactivity to
Mycobacterium gordonae.
RAPTOR readingsa
2
3
141.5
90.3

Channels
LODb

1
103.6

Baselines
B2
B3
B4

74.9
67.0
48.9

105.6
69.5
75.7

68.7
50.0
47.3

37.6
29.7
61.7

Mycobacterium
gordonae
concentration
(CFU/ml)
2.0 x 106
2.0 x 107
2.0 x 108

52.5
83.2
55.1

84.0
59.2
67.5

32.3
42.2
48.4

33.4
39.7
47.0

229.6

169.3

M. tuberculosis
concentration
(CFU/ml)
1.2 x 108
223.5c
317.7
a
Calculated change from previous reading (pA).
b
Limit of detection.
c
Boldfaced numbers indicate positive result.
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4
93.0

Table 12m: RAPTOR assay to test anti-M. tuberculosis antibody cross reactivity to
Mycobacterium intracellulare.
RAPTOR readingsa
2
3
118.9
53.7

Channels
LODb

1
94.7

Baselines
B2
B3
B4

58.8
61.3
35.4

75.7
53.6
84.4

38.0
21.9
27.6

48.6
44.9
49.6

Mycobacterium
intracellulare
concentration
(CFU/ml)
1.2 x 106
1.2 x 107
1.2 x 108

38.9
45.2
42.7

33.0
45.3
40.7

4.7
24.4
17.7

22.5
36.0
30.4

133.8

138.4

M. tuberculosis
concentration
(CFU/ml)
1.2 x 108
148.1c
196.2
a
Calculated change from previous reading (pA).
b
Limit of detection.
c
Boldfaced numbers indicate positive result.
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4
55.1

Table 13: Summary of cross reactivity studies using RAPTOR.
Bacterium
assayed
Staphylococcus aureus
Streptococcus pneumoniae
Escherichia coli K-12
Haemophilus influenzae
Klebsiella pneumoniae
Streptococcus agalactiae
Pseudomonas aeruginosa
Candida albicans
Mycobacterium rhodochrous
Proteus mirabilis
Mycobacterium smegmatis
Mycobacterium gordonae
Mycobacterium intracellulare

Concentrations
tested
(CFU/ml)
2.4 x 106
2.4 x 107
2.4 x 108
1.6 x 106
1.6 x 107
1.6 x 108
2.0 x 106
2.0 x 107
2.0 x 108
2.4 x 106
2.4 x 107
2.4 x 108
2.4 x 106
2.4 x 107
2.4 x 108
2.0 x 106
2.0 x 107
2.0 x 108
2.4 x 106
2.4 x 107
2.4 x 108
1.2 x 106
1.2 x 107
1.2 x 108
2.0 x 106
2.0 x 107
2.0 x 108
2.1 x 106
2.1 x 107
2.1 x 108
1.2 x 106
1.2 x 107
1.2 x 108
2.0 x 106
2.0 x 107
2.0 x 108
1.2 x 106
1.2 x 107
1.2 x 108

Number of
positive
channels
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

Total
channels
tested
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4

Validity of each experiment was confirmed by obtaining a positive value for
change from previous reading after M. tuberculosis sample at ~108 CFU/ml was tested at
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the end of each experiment. There was no positive detection observed when
microorganisms other than M. tuberculosis were tested using the M. tuberculosis
RAPTOR assay.
Western Blot Antibody Study
Western blots were used to determine whether the anti-M. tuberculosis antibody
cross reacted with any proteins and other molecules found in whole cells of the bacteria
studied in RAPTOR assays. All bacteria concentrations were adjusted to 1.2 x 108
CFU/ml by diluting cells in PBS (or in PBST for Mycobacterium species). Cells were
electrophoresed using SDS-PAGE then transferred to nitrocellulose membranes. After
blocking, the membranes were probed with anti-M. tuberculosis antibody at 2.5 µg/ml.
Secondary antibody, anti-rabbit IgG conjugated to alkaline phosphatase was used at a
concentration of 0.5 µg/ml. Only Mycobacterium smegmatis showed cross reactive
proteins in Western blots. Results are shown in Figure 14.
Molecular weight markers are visible in Figure 14. Lane 1 contains M.
tuberculosis cells and Lane 2 contains Mycobacterium smegmatis cells. The attenuated
M. tuberculosis and Mycobacterium smegmatis both had bands at 1.9 mm and 2.8 mm.
Band 1 in the attenuated M. tuberculosis and M. smegmatis lanes appears to be 24 kDa
and faint. Band 2, held in common by both bacteria, appears to be 45 kDa. Both bacteria
had two bands in common. Other cells that were tested were: attenuated M. tuberculosis,
Escherichia coli K-12, Haemophilus influenzae, Streptococcus agalactiae, Klebsiella
pneumoniae, Streptococcus pneumoniae, Staphylococcus aureus, Mycobacterium
rhodochrous, Proteus mirabilis, Pseudomonas aeruginosa, Mycobacterium smegmatis,
Candida albicans, Mycobacterium gordonae and Mycobacterium intracellulare.
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1

2

2

KDa
205
116
66
45
29
20

14.2

Figure 14: Western blot showing anti-M. tuberculosis antibody cross reaction with
Mycobacterium smegmatis proteins.
The sandwich immunoassays developed for use in both the Analyte 2000 and the
RAPTOR are rapid and very specific. No cross reactivity was observed with the
microorganisms of Candida albicans, Escherichia coli K-12, Haemophilus influenzae,
Klebsiella pneumoniae, Mycobacterium gordonae, Mycobacterium intracellulare,
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Mycobacterium rhodochrous, Mycobacterium smegmatis, Proteus mirabilis,
Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus agalactiae and
Streptococcus pneumoniae with the polyclonal M. tuberculosis antibodies used in the
development of an immunoassay for rapid detection of M. tuberculosis in these
biosensors. Some cross reactivity was observed with testing on ELISAs.
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Discussion
Development of a rapid method to detect M. tuberculosis from lung tissue at
autopsy would be a significant benefit to medical examiners’ offices and pathologists
worldwide. Rapid diagnosis would allow autopsy personnel exposed to an infected
decedent to obtain results within hours for possible exposure to M. tuberculosis. The
personnel could then be closely monitored for infection and begin treatment earlier, if
needed. RAPTOR results on lung tissue could be obtained potentially within three hours.
This study shows it is possible to detect M. tuberculosis in three hours using the
RAPTOR biosensor, instead of one month using current, conventional tests. Sample
preparation and assay protocols involve common laboratory practices and could easily
and quickly be learned and implemented by laboratory staff. The RAPTOR is user
friendly and could be used by medical examiner staff at time of need.
A problem encountered during assay development was the slightly elevated limit
of detection, as compared to E. coli O157:H7 biosensor assays. The biotin and Cy5
labeled antibody concentrations were lowered, which helped, but limit of detections were
still slightly elevated, as compared to E. coli O157:H7 assays. It is thought the antibody
to M. tuberculosis has some nonspecific binding, which would contribute to higher limits
of detection.
Before placing a sample into the Analyte or RAPTOR, it was necessary to ensure
clumps were not in the sample to be tested for M. tuberculosis. Removal of clumps was
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performed by sonication and/or homogenizing. If clumps were not removed, clogging
occurred in the sample port, leading to inconclusive results. It was necessary to remove
lung pieces from a sample ground with M. tuberculosis before running the sample
through the RAPTOR, to prevent clogging of the sample port and/or the channels of the
coupon.
Consistent detection was obtained at 106, 107 and 108 CFU/ml with M.
tuberculosis in PBST. However, when testing lung tissue with M. tuberculosis,
consistent detection was obtained only at 107 and 108 CFU/ml. This difference is thought
to be caused by dilution of the M. tuberculosis by lung blood during grinding.
The rapid detection of M. tuberculosis using the RAPTOR takes three hours.
Three hours is rapid, when compared to the minimum of one month for results based on
conventional tests. Even though the RAPTOR is fully automated, it would be desirable
to develop an even more rapid RAPTOR assay to detect M. tuberculosis. Development
of an even more rapid RAPTOR assay would involve quicker sample preparation
procedures and shorter incubation times.
An ELISA was performed with anti-M. tuberculosis and Freund’s adjuvant
complete to determine which of the different layers that resulted after centrifugation of
Freund’s adjuvant were most reactive with anti-M. tuberculosis. The white bottom pellet
was most reactive. The results obtained enabled similar concentrations to be used during
development of the Analyte 2000 assay for M. tuberculosis. A direct count could not be
performed with Freund’s adjuvant complete due to the oil. Even when the pellet was
rinsed and suspended in PBST, the oil caused interference in counting. Serial dilutions
were performed, and the concentration of the pellet was based on the Sigma Chemical
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Company approximated 1 mg/ml concentration of the Freund’s adjuvant complete. The
Analyte 2000 assay using Freund’s adjuvant complete was developed for rapid detection
of M. tuberculosis. The Freund’s adjuvant complete was subsequently tried in the
RAPTOR with unsuccessful results. The oil coated the waveguides, coupon, tubing and
other parts of the RAPTOR, interfering in detection. The oil coating did occur in the
Analyte 2000, but not to the extent observed in the RAPTOR.
Analyte 2000 and RAPTOR assays were successfully developed using live
attenuated M. tuberculosis. Direct counts were performed to determine approximate
concentrations of M. tuberculosis. The sensitivity of both assays was 106 CFU/ml. A
RAPTOR assay with M. tuberculosis seeded into decedent lung tissue was then
successfully developed with a sensitivity of 107 CFU/ml.
Specificity studies were performed with various microorganisms and the anti-M.
tuberculosis antibody. First an ELISA was performed. There was slight cross reactivity
observed with some of the other microorganisms: Escherichia coli K-12, Haemophilus
influenzae, Streptococcus agalactiae, Klebsiella pneumoniae, Streptococcus pneumoniae,
Staphylococcus aureus, Proteus mirabilis, Pseudomonas aeruginosa, Mycobacterium
smegmatis, Candida albicans, Mycobacterium gordonae and Mycobacterium
intracellulare. This cross reactivity was observed at the higher concentrations of
microorganisms.
RAPTOR assay specificity was performed on these microbes. No cross reactivity
was observed with any of the microorganisms. M. tuberculosis was run as a positive
control at the end of each assay and was detected in all assays.
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A Western blot was performed on these microorganisms. It was determined that
there was slight cross reactivity with anti-M. tuberculosis and Mycobacterium smegmatis.
M. tuberculosis and Mycobacterium smegmatis each showed two bands, signifying they
contain two similar proteins that are reactive with anti-M. tuberculosis antibody.
Potential cross reactivity issues with other microorganisms and anti-M.
tuberculosis may possibly be resolved by testing with a monoclonal M. tuberculosis
antibody. However, further study would be necessary.
An important aspect determined with the development of the M. tuberculosis
RAPTOR assay is that the sensitivity and specificity of the assay is dependent on the
antibodies used. Even though polyclonal antibodies were used in this study and no cross
reactivity was observed when testing specificity in the RAPTOR assays, the anti-M.
tuberculosis antibody did exhibit cross reactivity to other microorganisms when ELISA
was used for testing. ELISA studies showed small amounts of cross reactivity when high
concentrations of other microbes were tested. It may be that the anti-M. tuberculosis
antibody had a greater chance of sticking non-specifically to wells of ELISA plates than
to the waveguides used in RAPTOR assays. The Western blot demonstrated that the antiM. tuberculosis antibody did bind to specific molecules found in M. smegmatis and in M.
tuberculosis. The Western blot also demonstrated that the antibody was not cross
reactive with the microorganisms: Escherichia coli K-12, Haemophilus influenzae,
Streptococcus agalactiae, Klebsiella pneumoniae, Streptococcus pneumoniae,
Staphylococcus aureus, Proteus mirabilis, Pseudomonas aeruginosa, Candida albicans,
Mycobacterium gordonae and Mycobacterium intracellulare. During a M. tuberculosis
infection of the lungs, one may also have other microbial infections in the lungs. Some
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microbes alone can cause infections of the lungs with symptoms similar to M.
tuberculosis infections. Various microorganisms were tested, but do not represent all
possible microbial infections that may be found in the lungs. Cross reactivity studies
were also performed to determine if other microorganisms that may be present would
give false positive detection for M. tuberculosis, with or without the presence of M.
tuberculosis. The results suggest that only Mycobacterium smegmatis has the potential to
produce false positive results in RAPTOR assays. However, no false positives were
discovered when performing specificity RAPTOR assays with Mycobacterium
smegmatis.
Freund’s adjuvant complete was used in this study prior to USF Biosafety
Committee approval of attenuated M. tuberculosis. The adjuvant, which contained heat
killed M. tuberculosis H37Rv, could be used prior to such approval. However, the oil
presented problems in direct counts and in RAPTOR assays.
Attenuated M. tuberculosis (37, 68, 72) was used in this study because work was
performed in a Biosafety Level 2 facility. M. tuberculosis H37Rv was not used; its
testing requires a Biosafety Level 3 laboratory. It is possible that RAPTOR results may
be different when H37Rv is tested. H37Rv may test with better sensitivity, as it contains
all virulent genetic material. The studies described using H37Ra, however, do suggest
that the RAPTOR assay will detect the H37Rv strain at concentrations of >107 CFU/ml.
Future work could include developing a rapid assay to detect M. tuberculosis at
concentrations lower than 107 CFU/ml by improving capture efficiency of M.
tuberculosis on the waveguides. In a M. tuberculosis infection of the lung, the
concentration of M. tuberculosis is usually in the range of 107 to 109 CFU/ml (31).
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Current testing performed at the State Laboratory requires positive detection using
DNA probing and confirmation of growth on Lowenstein Jensen slants. The growth is a
confirmation of viable M. tuberculosis. The biosensor assay that was developed in this
study would be used as a screening test. If M. tuberculosis were detected, PCR
confirmation and viability testing would subsequently be performed. Since M.
tuberculosis grows so slowly (a generation time of 15-20 hours), confirmation of viability
usually takes at least a week. However, PCR confirmation and viability tests could be
immediately performed on M. tuberculosis recovered from biosensor waveguides as
reported in previous studies from our laboratory (45, 69, 76).
There is potential for development for rapid detection and diagnosis using the
RAPTOR for clinical specimens from living individuals, possibly cerebrospinal fluid,
blood, urine and sputum. Clinical specimens without M. tuberculosis infection could be
seeded with attenuated M. tuberculosis and similar procedures could be followed as was
done with the RAPTOR assays that used seeded decedent lung tissue. Cerebrospinal
fluid, blood and urine may be challenging matrices to test. These specimens may cause
overwhelming background interference when tested in the laboratory on the RAPTOR. If
background interference can be managed, variances in protocols may have to be
developed to adjust for the different matrices. Urine samples may require pH adjustment,
and sputum samples may require decontamination steps. It may be that M. tuberculosis
in cerebrospinal fluid, blood, urine and sputum may not be found in sufficient
concentrations to detect using the RAPTOR. The sensitivity of M. tuberculosis assays
may need to be improved before detection could be achieved.
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In order to determine if the biosensor assay with lung tissue seeded with
attenuated M. tuberculosis in this study is an accurate representation of a naturally
infected lung with M. tuberculosis, lung tissue from a naturally-infected lung with M.
tuberculosis should be tested on the biosensor. A Biosafety Level 3 facility would be
required for testing.
A rapid RAPTOR assay for the detection of M. tuberculosis in decedent lung
tissue was developed in this study. This assay offers potential for further development in
rapidly detecting M. tuberculosis in decedents, as well as possibly in living individuals.
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